Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Medartis Holding AG ( (CH:MED) ).
Medartis Holding AG reported a significant organic sales growth of 15.3% in the first half of 2025, driven by strong performance in the EMEA and USA regions. The company raised its sales forecast for the full year, reflecting confidence in its strategic initiatives, including the integration of NeoOrtho and KeriMedical, and the upcoming launch of its flagship product TOUCH in the USA. Despite challenges such as CHF appreciation and US tariffs, Medartis maintained a stable core EBITDA margin. The company’s efforts to strengthen its competitive position in the USA and Latin America, along with investments in R&D and digital offerings, are expected to drive future growth.
The most recent analyst rating on (CH:MED) stock is a Buy with a CHF86.00 price target. To see the full list of analyst forecasts on Medartis Holding AG stock, see the CH:MED Stock Forecast page.
More about Medartis Holding AG
Medartis Holding AG is a leading orthopedic company specializing in head and extremity surgery. The company focuses on providing innovative solutions for surgical procedures, with a strong market presence in regions such as EMEA and the USA.
Average Trading Volume: 4,486
Technical Sentiment Signal: Buy
Current Market Cap: CHF1.01B
For an in-depth examination of MED stock, go to TipRanks’ Overview page.